Giada Azzopardi

Giada Azzopardi

Auto-generated profile, based on publicly available information

Giada Azzopardi

Adult Critical Care Unit, The Royal London Hospital, Barts Health NHS Trust , London

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
TDThomas W. Davies
Thomas W. Davies
NWNaomi Watson
Naomi Watson
JPJames J. Pilkington
James J. Pilkington
TMThomas J. McClelland
Thomas J. McClelland
GAGiada Azzopardi
Giada Azzopardi
ZPZudin Puthucheary
Zudin Puthucheary
Background: The efficacy of creatine replacement through supplementation for the optimization of physical function in the population at risk of functional disability is unclear.Methods: We conducted a systematic literature search of MEDLINE, EMBASE, the Cochrane Library, and CINAHL from inception to November 2022. Studies included were randomized controlled trials (RCTs) comparing creatine supplementation with placebos in older adults and adults with chronic disease. The primary outcome was physical function measured by the sit‐to‐stand test after pooling data using random‐effects modeling. We also performed a Bayesian meta‐analysis to describe the treatment effect in probability terms. Secondary outcomes included other measures of physical function, muscle function, and body composition. The risk of bias was assessed using the Cochrane risk‐of‐bias tool.Results: We identified 33 RCTs, comprising 1076 participants. From six trials reporting the primary outcome, the pooled standardized mean difference (SMD) was 0.51 (95% confidence interval [CI]: 0.01–1.00; I2 = 62%; P = 0.04); using weakly informative priors, the posterior probability that creatine supplementation improves physical function was 66.7%. Upper‐body muscle strength (SMD: 0.25; 95% CI: 0.06–0.44; I2 = 0%; P = 0.01), handgrip strength (SMD 0.23; 95% CI: 0.01–0.45; I2 = 0%; P = 0.04), and lean tissue mass (MD 1.08 kg; 95% CI: 0.77–1.38; I2 = 26%; P < 0.01) improved with creatine supplementation. The quality of evidence for all outcomes was low or very low because of a high risk of bias.Conclusion: Creatine supplementation improves sit‐to‐stand performance, muscle function, and lean tissue mass. It is crucial to conduct high‐quality prospective RCTs to confirm these hypotheses (PROSPERO number, CRD42023354929).

1 May 2026 in Clinical Kidney Journal
Verified
Journal Article
Open access
GAGiada Azzopardi
Giada Azzopardi
TDThomas Davies
Thomas Davies
MLMyles J Lewis
Myles J Lewis
ZPZudin Puthucheary
Zudin Puthucheary
JPJohn R Prowle
John R Prowle
Background: Skeletal muscle wasting due to aging, acute illness, and chronic disease is associated with adverse outcomes including mortality, frailty, and multi-morbidity. We investigated the relationship of creatinine muscle index (CMI), a serum biological signature of muscle mass, in UK Biobank participants with gold standard muscle measurement and adverse outcomes. Method: We compared CMI with Magnetic Resonance Imaging (MRI) measured muscle mass in 33 799 participants using linear regression. We then assessed CMI’s ability to discriminate low muscle mass (≤2.5 SD below the mean). In the full UK Biobank cohort (n = 450 812), we utilized Cox-proportional hazards models to investigate associations between CMI with mortality, frailty and comorbidity. Results: CMI demonstrated moderate to good linear correlation with gold-standard MRI muscle mass measurements [R males: 0.68 (0.60–0.76); females: 0.65 (0.56–0.73)], after accounting for data imbalance. CMI discriminated muscle mass ≤2.5 standard deviations from the mean, with an area under the curve of 0.80 (95% CI:0.75–0.86) in males and 0.84 (95% CI:0.78–0.89) in females. CMI consistently decreased with increasing age, frailty and comorbidity. Over an 8-year follow-up, lower CMI was associated with higher morality: adjusted hazard ratio for the 25th vs 75th CMI centiles were 0.61 (95% CI: 0.58–0.66) in males and 0.72 (95% CI: 0.66–0.78) in females. Conclusions: In over 450 000 UK Biobank participants, low CMI was significantly associated with baseline comorbidity, frailty and survival on follow-up (independent of age, sex, and comorbidity). This study supports CMI as a potential biological signature for skeletal muscle wasting in clinical and research settings.